CEST for Prostate Biopsy
Advanced Metabolic MRI to Refine Targeted Prostate Biopsy
1 other identifier
interventional
20
1 country
1
Brief Summary
Samples of prostate tissue acquired by biopsy to determine whether there is cancer will sometimes not find cancer that is present. Conventionally, magnetic resonance imaging (MRI) is used to identify 12 areas to biopsy. We will use an advanced MRI method called magnetization transfer (MT) and chemical exchange saturation transfer (CEST) imaging to suggest two additional biopsy location. Our objectives are to determine 1) whether MT/CEST MRI can aid in the detection prostate cancer and 2) whether MT/CEST MRI can aid conventional MRI in risk stratification and to decide whether targeted prostate biopsy is justified.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2026
CompletedFirst Posted
Study publicly available on registry
August 25, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
Study Completion
Last participant's last visit for all outcomes
September 1, 2027
August 25, 2026
August 1, 2026
1 year
August 19, 2026
August 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Aiding the detection of prostate cancer
To determine whether MT/CEST MRI can aid in the detection of prostate cancer. The histopathological detection of cancer in biopsy cores will serve as a measure of outcome to which the MT/CEST MRI parameter and relaxation images will be compared.
1 year
Secondary Outcomes (1)
Aiding risk stratification and the decision whether targeted prostate biopsy is justified
1 year
Study Arms (1)
Diagnostic Test: Saturation Transfer (ST)-MRI
EXPERIMENTALNon-contrast magnetic resonance imaging "Saturation Transfer" scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)
Interventions
Saturation transfer MRI (chemical exchange saturation transfer and magnetization transfer) used to identify two additional biopsy locations in addition to those identified by conventional MRI.
Eligibility Criteria
You may qualify if:
- PI-RADS category 3 prostate cancer with upcoming targeted biopsy
You may not qualify if:
- Contraindications to MRI
- Prior radiotherapy
- Prior chemotherapy
- Prior prostate biopsy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Greg J Stanisz, PhD
Sunnybrook Research Institute
- PRINCIPAL INVESTIGATOR
Christopher Lim, MD
Sunnybrook Health Sciences Centre
- PRINCIPAL INVESTIGATOR
Danny Vesprini, MSc, MD
Sunnybrook Health Sciences Centre
- PRINCIPAL INVESTIGATOR
Stanley K Liu, MD, PhD
Sunnybrook Health Sciences Centre
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2026
First Posted
August 25, 2026
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Last Updated
August 25, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share